NASDAQ:BMRA Biomerica (BMRA) Stock Price, News & Analysis $3.72 -0.04 (-1.06%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomerica Stock (NASDAQ:BMRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomerica alerts:Sign Up Key Stats Today's Range$3.65▼$3.7550-Day Range$2.99▼$4.1452-Week Range$1.93▼$10.16Volume4,392 shsAverage Volume432,949 shsMarket Capitalization$9.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Read More Biomerica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreBMRA MarketRank™: Biomerica scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Biomerica. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomerica is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomerica is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomerica has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomerica's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.00% of the float of Biomerica has been sold short.Short Interest Ratio / Days to CoverBiomerica has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomerica has recently decreased by 13.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomerica does not currently pay a dividend.Dividend GrowthBiomerica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.00% of the float of Biomerica has been sold short.Short Interest Ratio / Days to CoverBiomerica has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomerica has recently decreased by 13.37%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentBiomerica has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biomerica this week, compared to 1 article on an average week.Search Interest3 people have searched for BMRA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Biomerica to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomerica insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.28% of the stock of Biomerica is held by institutions.Read more about Biomerica's insider trading history. Receive BMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRA Stock News HeadlinesInFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code - MorningstarJuly 3, 2025 | morningstar.comMBiomerica, Inc. Secures PLA Code for inFoods® IBS Test to Enhance Patient Access and Insurance Reimbursement - NasdaqJuly 3, 2025 | nasdaq.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 29 at 2:00 AM | Brownstone Research (Ad)Biomerica Secures PLA Code For InFoods IBS Test, Advancing Reimbursement Access - NasdaqJuly 3, 2025 | nasdaq.comBiomerica, Inc. Secures PLA Code for inFoods® IBS Test to Enhance Patient Access and Insurance ReimbursementJuly 2, 2025 | quiverquant.comQInFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) CodeJuly 2, 2025 | globenewswire.comClinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer - MorningstarJune 27, 2025 | morningstar.comMClinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial OfficerJune 26, 2025 | finance.yahoo.comSee More Headlines BMRA Stock Analysis - Frequently Asked Questions How have BMRA shares performed this year? Biomerica's stock was trading at $2.4008 at the beginning of 2025. Since then, BMRA stock has increased by 54.9% and is now trading at $3.72. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) released its quarterly earnings results on Monday, April, 14th. The company reported ($0.48) earnings per share for the quarter. The firm earned $1.12 million during the quarter. Biomerica had a negative net margin of 85.42% and a negative trailing twelve-month return on equity of 85.90%. When did Biomerica's stock split? Biomerica's stock reverse split on the morning of Monday, April 21st 2025.The 1-8 reverse split was announced on Wednesday, April 16th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Biomerica? Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings4/14/2025Today7/29/2025Next Earnings (Estimated)8/27/2025Fiscal Year End5/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMRA CIK73290 Webwww.biomerica.com Phone(949) 645-2111Fax949-553-1231Employees60Year Founded1971Profitability EPS (Trailing Twelve Months)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.98 million Net Margins-85.42% Pretax Margin-85.35% Return on Equity-85.90% Return on Assets-61.06% Debt Debt-to-Equity RatioN/A Current Ratio3.76 Quick Ratio2.76 Sales & Book Value Annual Sales$5.41 million Price / Sales1.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.13 per share Price / Book1.19Miscellaneous Outstanding Shares2,550,000Free Float2,164,000Market Cap$9.49 million OptionableOptionable Beta0.35 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BMRA) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.